Bree Aldridge

Professor

Tufts University

United States

Research Interests

Explore related searches

Professors in United States Professors in Microbiology Microbiology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Bree Aldridge is a faculty member at Tufts University in the United States. Her research primarily focuses on tuberculosis and antibiotic resistance, with recent publications covering topics such as drug action mechanisms, treatment efficacy, and innovative methodologies in microbiology. Her work includes significant contributions to understanding bactericidal responses and drug interactions in various pathogens.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Xin Wang

Harvard T.H. Chan School of Public Health

UNITED STATES

View details

Anne McCabe

Assistant Professor

Albany College of Pharmacy and Health Sciences

UNITED STATES

View details

Richard J. Wall

Assistant Professor

London School of Hygiene & Tropical Medicine

UNITED KINGDOM

View details

Rob Christiaan van Wijk

Assistant professor / Principal investigator "Translational Immuno-Pharmacology"

Leiden University

NETHERLANDS

View details

Trever Smith II

Research Assistant Professor

Tufts University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bree Aldridge

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Integration of multi-modal measurements identifies critical mechanisms of tuberculosis drug action.

Erratum for Peroutka-Bigus et al., “Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease”

Targeting de novo purine biosynthesis for tuberculosis treatment.

Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease

Large-scale combination screens reveal small-molecule sensitization of antibiotic-resistant gram-negative ESKAPE pathogens.

Predicting tuberculosis drug efficacy in preclinical and clinical models from in vitro data.

In vitro identification of underutilized β-lactam combinations against methicillin-resistant Staphylococcus aureus bacteremia isolates

Critical role of growth medium for detecting drug interactions in Gram-negative bacteria that model in vivo responses

Single-cell imaging of the Mycobacterium tuberculosis cell cycle reveals linear and heterogenous growth

Advances in the design of combination therapies for the treatment of tuberculosis

Semi-automated colony-forming unit counting for biosafety level 3 laboratories.

Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements

Types and functions of heterogeneity in mycobacteria

Identification of cell wall synthesis inhibitors active against Mycobacterium tuberculosis by competitive activity-based protein profiling

Leveraging laboratory and clinical studies to design effective antibiotic combination therapy

The Tuberculosis Drug Accelerator at year 10: what have we learned?

Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis

Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl-1 Inhibitor AZD5991.

Morphological profiling of tubercle bacilli identifies drug pathways of action.

Collaborators (5)

Xin Wang

Anne McCabe

Richard J. Wall

Rob Christiaan van Wijk

Trever Smith II

Make your next move.